DRG Market Assessment reports

Currently available therapies for the treatment of Ankylosing Spondylitis (AS) target primarily the signs and symptoms of the disease; scant data exist demonstrating an impact on structural…

Postherpetic neuralgia (PHN) is a chronic pain condition that requires prolonged treatment; this condition affected less than 246,000 people in the United States in 2013. Despite the modest size of…

LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer…

This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the…

What Are the Key Areas of Opportunity for Differentiation According to Dermatologists and Payers? Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe…

What Are the Key Areas of Opportunity for Differentiation According to Dermatologists and Payers? Affecting more than 3 million people in the major pharmaceutical markets, moderate to severe…

The increase in U.S. Medicare and Medicaid beneficiaries has been accompanied by growth in managed care’s presence in those two sectors of health benefits. In 2014, 30% of all Medicare…

A syndicated report that will provide information on various hyperphosphatemia market dynamics. It provides insight into practice patterns, attitudes and perceptions, and current and projected…

Several newly approved agents for asthma together with others seeking approval are expanding the range of therapeutic options for this disease in Brazil and Mexico. Drugs such as the inhaled…

Tens of millions of people in the United States have a lipid abnormality or dyslipidemia. Given the inherent risk of cardiovascular disease that dyslipidemias carry, multiple prescription therapies…

With more than 32 million people in the United States diagnosed with osteoarthritis (OA), it is the most common type of arthritis and a leading cause of disability. Among the symptoms…

High unmet need exists for severe, refractory asthma patients, for whom Genentech/Novartis’s Xolair is currently the only therapeutic option. Together with a number of newly approved agents for…